Investment

MLB-001 is MindLab’s first‑in‑class, morphine‑based combination therapy

Engineered to solve the central
contradiction of modern pain care: deliver morphine‑level relief while sharply reducing euphoria, respiratory risk, and abuse liability.

Our Clinical Solution Commercial Opportunity Investment Thesis

Our Clinical Solution

Why MLB-001 Matters

An independent AI‑driven assessment by GNQ Insilico confirms MLB‑001 as a true next‑generation morphine replacement

12-19%
Higher
SPID‑48 pain‑relief scores
50%
Morphine Sparing
SPID‑48 pain‑relief scores
~3×
Longer Duration
~8 hours compared to 3 hours with morphine

MLB-001 widens
the safety window

40% Reduction

in predicted respiratory‑depression risk

(7.3% vs 12.9% for morphine)

No Additional

physical‑dependence risk

(Related combinations demonstrate ~20% reductions in drug‑liking and composite abuse‑liability scores.)

For Hospitals and Payors,
this translates to

Fewer doses required per patient

Fewer breakthrough‑pain events

Reduction in misuse, diversion, and addiction risk

Without sacrifice in efficacy

Commercial Opportunity

Peak sales projection: $1.1B-$2.9B based on 5-13% market share

With credible 5-13% penetration of the $32B global morphine market and upside from sickle‑cell and other rare‑disease pain indications.
Using conservative assumptions and standard morphine pricing
Validated Proof of concept
$1.13B-$2.94B
peak sales projection based on 5-13% market share
5-13%
market penetration
of the $17bn global morphine marker

Pricing Strategy

MLB-001 will be priced at parity with Morphine

Positioning it as a “drop‑in” replacement rather than a premium product, and driving a capital‑efficient path to Phase II/III value inflection where modeled post‑trial valuations reach

Learn More

Projected Value Inflection

MindLab’s valuation is expected to rise significantly with clinical progress

Mindlab’s valuation could reach upside of $5Bn+, if GNQ’s safety and euphoria‑reduction projections are replicated in humans

Value inflection graph

MLB-001 is not just a slightly improved opioid. It is a fundamentally safer, more effective, and more predictable alternative to morphine.

With the opioid crisis still an unmet medical need and no approved opioid offering reduced euphoria and lower abuse liability, MLB‑001 is positioned to become the first true opioid‑class disruptor in decades. Contact us to find out more.

Get in touch